Published in Nat Med on June 24, 2002
Leukaemogenesis: more than mutant genes. Nat Rev Cancer (2010) 2.16
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A (2003) 1.69
Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci U S A (2007) 1.46
The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol (2004) 1.43
The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol (2003) 1.38
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci (Landmark Ed) (2012) 1.37
p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood (2007) 1.18
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J (2004) 1.16
Mtgr1 is a transcriptional corepressor that is required for maintenance of the secretory cell lineage in the small intestine. Mol Cell Biol (2005) 1.16
AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proc Natl Acad Sci U S A (2005) 1.14
Epigenetic consequences of AML1-ETO action at the human c-FMS locus. EMBO J (2003) 1.14
The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle (2013) 1.08
Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res (2007) 1.07
Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene (2008) 1.07
Runx1 loss minimally impacts long-term hematopoietic stem cells. PLoS One (2011) 1.06
Myeloid translocation gene family members associate with T-cell factors (TCFs) and influence TCF-dependent transcription. Mol Cell Biol (2007) 1.06
AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood (2010) 1.05
RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene (2009) 1.03
Transcriptional regulation of the human MIP-1alpha promoter by RUNX1 and MOZ. Nucleic Acids Res (2003) 1.03
A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS One (2013) 1.02
Btg2 enhances retinoic acid-induced differentiation by modulating histone H4 methylation and acetylation. Mol Cell Biol (2006) 0.97
RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response. Int J Genomics (2013) 0.95
Runx-dependent expression of PKC is critical for cell survival in the sea urchin embryo. BMC Biol (2005) 0.94
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res (2008) 0.94
Runx regulation of sphingolipid metabolism and survival signaling. Cancer Res (2010) 0.93
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J (2016) 0.93
The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer (2004) 0.92
Oncogene-induced senescence: an essential role for Runx. Cell Cycle (2008) 0.92
RUNX1: A microRNA hub in normal and malignant hematopoiesis. Int J Mol Sci (2013) 0.91
Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol Cell Biol (2005) 0.90
Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett (2006) 0.89
The frequency of NPM1 mutations in childhood acute myeloid leukemia. J Hematol Oncol (2010) 0.89
AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation. Leukemia (2015) 0.89
Chimeric negative regulation of p14ARF and TBX1 by a t(9;22) translocation associated with melanoma, deafness, and DNA repair deficiency. Hum Mutat (2013) 0.87
Runt-related transcription factor 1 (RUNX1) stimulates tumor suppressor p53 protein in response to DNA damage through complex formation and acetylation. J Biol Chem (2012) 0.87
Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem (2013) 0.86
Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. EMBO J (2005) 0.85
Transgenic and knockout mice models to reveal the functions of tumor suppressor genes. Clin Med Insights Oncol (2011) 0.85
In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML. PLoS One (2010) 0.85
Myeloid translocation gene 16 is required for maintenance of haematopoietic stem cell quiescence. EMBO J (2012) 0.83
Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation. Am J Clin Exp Urol (2014) 0.82
Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon. Clin Epigenetics (2015) 0.82
Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. Blood Cells Mol Dis (2007) 0.82
DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance. Chromosoma (2014) 0.81
RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1). J Cell Biochem (2010) 0.80
AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia. Cancer Res (2010) 0.79
Comparison of plasmid DNA versus PCR amplified gene of insert DNA for nucleofection in Kasumi-1 cells. Cytotechnology (2014) 0.78
Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia. Proc Natl Acad Sci U S A (2003) 0.77
The DAC system and associations with acute leukemias and myelodysplastic syndromes. Invest New Drugs (2010) 0.77
Roles of p15Ink4b and p16Ink4a in myeloid differentiation and RUNX1-ETO-associated acute myeloid leukemia. Leuk Res (2007) 0.77
Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation. Biochim Biophys Acta (2015) 0.77
Dynamics of ARF regulation that control senescence and cancer. BMB Rep (2016) 0.75
Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype. Am J Hematol (2011) 0.75
New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins. Front Biol (Beijing) (2016) 0.75
Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report. Breast Care (Basel) (2016) 0.75
Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia. Haematologica (2016) 0.75
Role of RUNX1 in hematological malignancies. Blood (2017) 0.75
Haploinsufficient tumor suppressor genes. Adv Med Biol (2017) 0.75
Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature (2012) 18.23
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
Tenets of PTEN tumor suppression. Cell (2008) 8.61
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene (2003) 7.90
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 7.02
Does the ribosome translate cancer? Nat Rev Cancer (2003) 6.89
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 5.79
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet (2004) 5.55
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Nucleophosmin and cancer. Nat Rev Cancer (2006) 4.82
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 4.49
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19
The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol (2008) 4.15
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15
Role of nucleophosmin in embryonic development and tumorigenesis. Nature (2005) 4.09
Sex differences in drug abuse. Front Neuroendocrinol (2007) 4.01
The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell (2005) 3.96
SUMO modification of Huntingtin and Huntington's disease pathology. Science (2004) 3.85
Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater (2011) 3.83
Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development (2004) 3.75
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell (2011) 3.71
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood (2009) 3.69
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 3.53
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50
A continuum model for tumour suppression. Nature (2011) 3.48
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
Over 20% of human transcripts might form sense-antisense pairs. Nucleic Acids Res (2004) 3.45
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med (2012) 3.33
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol (2005) 3.29
The role of PML in tumor suppression. Cell (2002) 3.28
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest (2009) 3.23
The mechanisms of PML-nuclear body formation. Mol Cell (2006) 3.22
PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science (2010) 3.21
Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science (2003) 3.18
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 3.17
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med (2012) 3.03
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 3.01
Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature (2007) 3.01
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 3.00
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol (2009) 2.97
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (2007) 2.92
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
Cytoplasmic PML function in TGF-beta signalling. Nature (2004) 2.89
Identifying novel transcripts and novel genes in the human genome by using novel SAGE tags. Proc Natl Acad Sci U S A (2002) 2.87
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med (2008) 2.85
The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol (2011) 2.79
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev (2006) 2.76
Pro-senescence therapy for cancer treatment. Nat Rev Cancer (2011) 2.75
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell (2008) 2.71
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71
Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J Biol Chem (2005) 2.68
Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol (2013) 2.67
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer (2013) 2.59
Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol (2005) 2.55
Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood (2009) 2.54
Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol (2008) 2.54
Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell (2003) 2.53
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53
A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res (2006) 2.50
Analysis of protein dynamics at active, stalled, and collapsed replication forks. Genes Dev (2011) 2.47
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46
PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol (2004) 2.45
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J (2008) 2.44
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood (2005) 2.44